Medical experts review therapy options for metastatic colorectal cancer after FOLFOX/FOLFIRI, emphasizing regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib due to the rarity of ...
Standard adjuvant chemotherapy for stage III colon cancer consists of a fluoropyrimidine-plus-oxaliplatin regimen. Whether the addition of atezolizumab (an anti–programmed death ligand 1 agent) to a ...
Amivantamab combined with FOLFOX or FOLFIRI showed a 51% overall response rate in RAS/BRAF wild-type mCRC patients, with a median progression-free survival of 9.2 months. The study highlighted notable ...
Three-year and five-year outcomes of a phase II study of perioperative CapeOx therapy for advanced gastric cancer with extensive lymph node metastasis (OGSG1701). Trifluridine/tipiracil and ...
Chemoradiotherapy for locally advanced rectal cancer is associated with toxic effects. Whether preoperative FOLFOX chemotherapy could allow patients to safely avoid chemoradiotherapy is unknown. New ...
An exploratory analysis of the genetic alteration associated with early-onset gastric and colorectal cancer using a large-scale nationwide database of Japan (C-CAT). This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results